December 20, 2025 01:20 pm (IST)
Follow us:
Pharma major Lupin completes its acquisition of US-based GAVIS
Mumbai, Mar 9 (IBNS): Pharma major Lupin Limited (Lupin) announced on Wednesday that it has completed its acquisition of privately held US-based GAVIS Pharmaceuticals LLC and Novel Laboratories Inc. (GAVIS).
Lupin had announced the acquisition on July 23, 2015.
The acquisition enhances Lupin’s scale in the US generic market and also broadens its pipeline in dermatology, controlled substance products and other high-value and niche generics.
The US-based manufacturing & research organization of GAVIS will complement Lupin’s Coral Springs, Florida based R&D center for Inhalation, according to the company.
GAVIS’s New Jersey based manufacturing facility also becomes Lupin’s first manufacturing site in the US.
New Jersey based GAVIS is a privately held company specializing in formulation development, manufacturing, packaging, sales, marketing, and distribution of pharmaceuticals products.
GAVIS has 62 ANDA filings pending approval with the US FDA and a pipeline of over 65+ products under development. 72% of these filings pending approvals represent niche dosage forms with 18 Para IVs and 8 FTFs products. GAVIS’s pending approvals address a market of over USD 9 billion.
The combined company will have a portfolio of over 120 in-market products, over 185 cumulative filings pending approval and a deep pipeline of products under development for the US.
The acquisition creates the fifth largest pipeline of ANDA filings with the US FDA, addressing a USD 63.8 billion market.
Lupin has 37 First-to-File (FTF) products, which includes 17 exclusive FTF opportunities.
Lupin and GAVIS combined would now have over 45 FTFs.
Commenting on the transaction, Vinita Gupta, Chief Executive Officer, Lupin Limited said, “We are very pleased to have completed our acquisition of Gavis. The Gavis portfolio augments our US business and niche generic pipeline. We plan to leverage the formulation expertise of Gavis to enhance both Lupin’s generic as well as specialty pipeline.”
Head-quartered in Mumbai, Lupin is a transnational pharmaceutical company producing and developing a wide range of branded and generic formulations, biotechnology products and APIs globally. The company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership positions in the Anti-TB and Cephalosporin segment.
Support Our Journalism
We cannot do without you.. your contribution supports unbiased journalism
IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.
Support objective journalism for a small contribution.
Latest Headlines
Tata AIA launches multicap opportunities fund
Fri, Dec 19 2025
IPO fireworks! ICICI Prudential AMC pops 20% on market debut
Fri, Dec 19 2025
Bharti Airtel announces top leadership changes; Gopal Vittal to become Executive Vice Chairman
Thu, Dec 18 2025
TCS bets big on AI, shares spike as company reveals ambitious plan
Thu, Dec 18 2025
Meesho’s wild ride: Hits record market cap, then suddenly slides
Thu, Dec 18 2025
SBI rolls out YONO 2.0! Banking gets a major digital upgrade
Wed, Dec 17 2025
Nephrocare IPO pops on debut, dialysis major lists at 7% premium
Wed, Dec 17 2025